Navigation Links
Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
Date:3/19/2008

- Additional data presentation on picoplatin overcoming platinum resistance

in small cell lung cancer -

SOUTH SAN FRANCISCO, Calif., March 19 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced that preliminary data from a Phase 1 trial of an oral formulation of picoplatin in patients with solid tumors will be presented at the 2008 American Association for Cancer Research meeting to be held from April 12-16 in San Diego, CA. In addition, preclinical data of picoplatin overcoming platinum resistant small cell lung cancer cells in platinum resistant cell lines will also be presented at a separate poster presentation.

Details are as follows:

-- A Phase 1 randomized crossover picoplatin bioavailability

pharmacokinetics and pharmacodynamics study.

Abstract #209, Session ID: Clinical Research 1;

Yee L, Sharma S, Breitz H, Karlin D, Phillips A, Houston S, Saleh M.

General Poster Session Sunday April 13, 8:00 AM PT.

-- Picoplatin overcomes resistance in small cell lung cancer cell lines

treated with other platinum-based chemotherapeutics.

Abstract #713, Session ID: Experimental Molecular Therapeutics 3;

Parham C, Shocron E, McMahon G, Patel N.

General Poster Session Sunday April 13, 8:00 AM PT.

Picoplatin is the Company's lead product candidate under investigation in three clinical trials.

About Picoplatin

Picoplatin is a chemotherapeutic agent that has an improved safety profile compared to existing platinum-based chemotherapeutics. It was designed to overcome platinum resistance associated with the treatment of
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
2. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
3. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
5. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
6. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
7. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
8. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
9. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
10. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... NeuroCall, Inc., ("NeuroCall") announced today that it ... Teleneurology services. Dr. Ricardo Garcia-Rivera , Founder and ... proud that our quality of service has been recognized ... lifesaving support and continuity of care to patients of ... the United States ." NeuroCall ...
(Date:10/1/2014)... , Oct. 1, 2014 Quantum Materials ... volume production of photoactive quantum dots for use ... While offering numerous advantages for solar power generation, ... quantities of quantum dots with which to develop ... them from commercial utilization and acceptance. The company ...
(Date:10/1/2014)... Sophia Genetics, leader européen ... l,analyse des données issues du SNG (séquençage nouvelle ... in vitro (IVD) du gène CFTR permettant aux ... dans un seul essai SGN. La solution CE-IVD ... de variantes par l,intermédiaire d,un seul essai SGN, ...
Breaking Medicine Technology:NeuroCall Awarded Joint Commission Accreditation 2Quantum Materials Scaling Up Photoactive Quantum Dot Production for Solar Power Generation 2Quantum Materials Scaling Up Photoactive Quantum Dot Production for Solar Power Generation 3Sophia Genetics lance une analyse complète du gène CFTR dans un essai clinique SGN 2Sophia Genetics lance une analyse complète du gène CFTR dans un essai clinique SGN 3
... SADDLE BROOK, N.J., April 27, 2011 Okay, so ... day, but these two working moms are certainly creating ... two high-achieving working moms with formidable educational credentials on ... entrepreneurial detour, something truly unexpected happened...they started selling the ...
... 27, 2011 Wolters Kluwer Health, a leading ... and institutions in medicine, nursing, allied health and pharmacy, ... to acquire Lexi-Comp, Inc., a leading global provider of ... The acquisition is the latest in a series of ...
Cached Medicine Technology:Not Your Average Working Moms 2Wolters Kluwer Health to Acquire Leading Global Drug Information Provider Lexi-Comp 2Wolters Kluwer Health to Acquire Leading Global Drug Information Provider Lexi-Comp 3Wolters Kluwer Health to Acquire Leading Global Drug Information Provider Lexi-Comp 4
(Date:10/1/2014)... 2014 NoteSwift Inc., announced today their ... 12.1 and 13.0. NoteSwift is the bridge between the ... navigate and document clinical information at the point of ... a patient note by more than half – and ... pain points providers state impedes EHR use according to ...
(Date:10/1/2014)... On Sept. 9, Chapín Coffee was selected ... Stewart American Made Awards (MSAMAs), an annual competition in ... the fields of crafts, design, food and style. ... in the MSAMAs, which celebrates entrepreneurs and artisans who ... communities and changing the way we shop, work and ...
(Date:10/1/2014)... Deland, Florida (PRWEB) October 01, 2014 ... to promote awareness and early detection plans while raising ... to support Breast Cancer Awareness Month in ... Water also wants to promote the importance of having ... contaminated drinking water may be linked to certain forms ...
(Date:10/1/2014)... 2014 Today marks the final day ... Institute in Oxnard and Woodland Hills, Calif., is in ... rehabilitation training. , “Speaking to this group of specialists ... to get the help and care they deserve,” Dr. ... previous dental work, providing cosmetic dentistry, correcting bite issues, ...
(Date:10/1/2014)... After undergoing a trial-and-error process in an ... join, Living Well Assisted Living at Home recently joined ... the home of its headquarters. , Although Living Well’s ... thought of adding one more activity to their busy ... the right chamber to join because membership in the ...
Breaking Medicine News(10 mins):Health News:NoteSwift Joins Allscripts Developer Program 2Health News:NoteSwift Joins Allscripts Developer Program 3Health News:Chicago Coffee Start-up Makes a Big Impact, Earns National Recognition 2Health News:Pelican Water Supports Breast Cancer Awareness Month with Order Donations 2Health News:Internationally Respected Oxnard Dentist Concludes All-on-4™ Dental Implants Training Today 2Health News:Internationally Respected Oxnard Dentist Concludes All-on-4™ Dental Implants Training Today 3Health News:Internationally Respected Oxnard Dentist Concludes All-on-4™ Dental Implants Training Today 4Health News:Internationally Respected Oxnard Dentist Concludes All-on-4™ Dental Implants Training Today 5Health News:Living Well Joins San Rafael Chamber of Commerce 2Health News:Living Well Joins San Rafael Chamber of Commerce 3
... rules for the first time forced players to limit the ... had to strategize how pitchers were used more carefully. ... under could throw up to six innings per week and ... in reported cases of young pitchers experiencing arm and shoulder ...
... 4 Health information,technology (HIT) is a powerful ... it must be implemented to interact with other ... to a new report by,BearingPoint, prepared for the ... a nonpartisan independent body based in Washington,but overseen ...
... Oct. 4 Hooper Holmes,(Amex: HH ) ... training,program for all paramedical examiners who have not ... training system,will be rolled out in November with ... same high quality education and training from the ...
... - Data Presented This Week at Major Medical Meeting Reinforce ... Broader Spectrum Pneumococcal ... division of Wyeth (NYSE: WYE ), comments on studies ... the Infectious Diseases,Society of America (IDSA) concerning PREVNAR(R) (Pneumococcal 7-valent,Conjugate ...
... Oct 4 Anesiva, Inc.,(Nasdaq: ANSV ) ... for the,investment community to review the company,s launch ... injection system. The briefing will take place on ... Eastern Time in New York City. To,access the ...
... Growth, ALISO VIEJO, Calif., Oct. 4 ... and services resource for,pathologists, oncologists and the pharmaceutical ... veteran Michael J. Pellini,M.D. has been named Chief ... to President and Chief Executive Officer,Ronald A. Andrews, ...
Cached Medicine News:Health News:How pitching changes little leaguers' shoulders 2Health News:How pitching changes little leaguers' shoulders 3Health News:New Report Finds Information Technology Essential But Not Sufficient in Long-Term Care 2Health News:New Report Finds Information Technology Essential But Not Sufficient in Long-Term Care 3Health News:New Report Finds Information Technology Essential But Not Sufficient in Long-Term Care 4Health News:Portamedic Launches New Examiner Training Program 2Health News:Portamedic Launches New Examiner Training Program 3Health News:Wyeth Comments on PREVNAR and Trends in Pneumococcal Disease 2Health News:Wyeth Comments on PREVNAR and Trends in Pneumococcal Disease 3Health News:Wyeth Comments on PREVNAR and Trends in Pneumococcal Disease 4Health News:Anesiva to Unveil Zingo(TM) Commercialization Plans 2Health News:Clarient Names Michael J. Pellini, M.D. Chief Operating Officer 2Health News:Clarient Names Michael J. Pellini, M.D. Chief Operating Officer 3Health News:Clarient Names Michael J. Pellini, M.D. Chief Operating Officer 4
... femoral option and tibial insert which provides a ... degrees of flexion to induce a smooth stable ... of flexion. Femoral component comes in a PS ... constrained tibial insert in conjunction with the femur ...
... True to its leadership role within the ... clinical experience of the industry's leading fixed-bearing ... Knee System, with the clinically proven technology ... leading rotating platform knee. ,The result is ...
... The Femoral component of ... soft tissue and bony destruction ... a high rate of long ... for minimum bone resection and ...
... Knee System is taking total knee replacement to ... of clinical experience. One thing has become clear ... several choices for their patients. Surgeon choice ... factor in long-term patient satisfaction. Biomet responded to ...
Medicine Products: